Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Speedy Summary of ASH25 progress for aggressive lymphoma, example: DLBCL focused on CAR-T and bispecific antibody immunotherapy.”
Watch the discussion on Medical Digest Congress Report.
More posts about ASH25.